[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364092-105":59,"doc-detail-364092-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","development-and-validation-of-a-radiomics-dosiomics-model-for-predicting-radiotherapy-response-in-locally-advanced-unresectable-non-small-cell-lung-cancer-a-multicenter-study","Development and validation of a radiomics-dosiomics model for predicting radiotherapy response in locally advanced, unresectable non-small cell lung cancer: a multicenter study","","Early assessment of treatment response is crucial for optimizing cancer management during radiotherapy. This multicenter study develops and validates a machine learning model that integrates radiomics, dosiomics, and clinical characteristics to predict response in patients with locally advanced, unresectable non-small cell lung cancer (NSCLC). Data from 222 patients were split into training, internal validation, and external validation cohorts. Objective response rate (ORR) and progression-free survival (PFS) were evaluated using ROC, DeLong test, DCA, Kaplan-Meier analysis, and Integrated Brier Score. The combined radiomics-dosiomics-clinical approach outperformed clinical-only models, improving predictive accuracy and supporting better patient monitoring.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-and-validation-of-a-radiomics-dosiomics-model-for-predicting-radiotherapy-response-in-locally-advanced-unresectable-non-small-cell-lung-cancer-a-multicenter-study/364092/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-and-validation-of-a-radiomics-dosiomics-model-for-predicting-radiotherapy-response-in-locally-advanced-unresectable-non-small-cell-lung-cancer-a-multicenter-study/364092.png","ImageObject",300,407,{"name":92,"@type":93},"anakgang17","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of this study?","Question",{"text":112,"@type":113},"To develop and validate a machine learning model that combines radiomics, dosiomics, and clinical factors to predict radiotherapy response in locally advanced, unresectable NSCLC.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the patients grouped for training and validation?",{"text":117,"@type":113},"A total of 222 patients were divided into training (n = 110), internal validation (n = 28), and external validation (n = 84) cohorts.",{"name":119,"@type":110,"acceptedAnswer":120},"Which outcomes were predicted by the models?",{"text":121,"@type":113},"The study predicted objective response rate (ORR) and progression-free survival (PFS) using radiomics, dosiomics, and clinical characteristics.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},364092,1790863045,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nDevelopment and validation of a radiomics-dosiomics model for predicting radiotherapy response in locally advanced, unresectable non-small cell lung cancer: a multicenter study  \nXun Wang1,6, Xiufen Sun2,6, Yueqin Chen1, Guqing Zhang1, Shucheng Ye3, Aiping Zhang4, Huipeng Yang5, Zhanguo Sun1,6􀀍 & Shuang Ge3,6􀀍  \nEarly assessment of treatment response is essential for optimizing cancer management, as it allows timely interventions during the course of therapy, potentially improving cancer control and clinical outcomes. In this study, we aimed to develop and validate a machine learning model integrating radiomics, dosiomics, and clinical characteristics to predict response to radiotherapy in patients with locally advanced, unresectable non-small cell lung cancer (NSCLC). A total of 222 patients across multiple centers who received radiotherapy for NSCLC were enrolled and divided into training (n = 110), internal validation (n = 28), and external validation (n = 84) cohorts. Objective response rate (ORR) and progression-free survival (PFS) were predicted using models based on radiomics, dosiomics, and clinical characteristics. Model performance was evaluated using receiver operating characteristic (ROC) curves, DeLong test, decision curve analysis (DCA), Kaplan-Meier survival analysis, and Integrated Brier Score (IBS). The clinical models, CORR and CPFS (both based on planning target volume [PTV] and lymphocyte count) were compared with combined radiomics–dosiomics–clinical models (RDCORR and RDCPFS). For ORR prediction, RDCORR achieved AUCs of 0.901, 0.894, and 0.869 in the training, internal validation, and external validation cohorts, outperforming CORR (AUCs of 0.723, 0.606, and 0.723), with p \u003C 0.05. DCA indicated that RDCORR outperformed CORR, providing a higher overall net benefit. For PFS prediction, RDCPFS yielded higher concordance indices (0.805, 0.730, and 0.743 in the training, internal validation, and external validation cohorts) than CPFS (0.679, 0.699, and 0.640, respectively) . RDCPFS showed the lowest IBS across all cohorts (0.092, 0.107, and 0.093, respectively) compared with CPFS and the reference model, indicating better predictive accuracy. The combined model integrating radiomics, dosiomics, and clinical characteristics enhances the prediction of radiotherapy response in locally advanced, unresectable NSCLC, facilitating improved patient monitoring and more effective adjuvant clinical trial design.  \nKeywords Radiomics, Dosiomics, Radiotherapy, Objective response rate, Progression-free survival, Nonsmall cell lung cancer  \nAbbreviations  \nC Clinical model  \n1Department of Medical Imaging, Affiliated Hospital of Jining Medical University, Guhuai Road, Jining 272000, Shandong, China. 2Department of Clinical Laboratory, Jining Cancer Hospital, Jianshe North Road, Jining 272123, Shandong, China. 3Department of Radiation Oncology, Affiliated Hospital of Jining Medical University, Guhuai Road, Jining 272000, Shandong, China. 4Department of Radiation Oncology, Jining Cancer Hospital, Jianshe North Road, Jining 272123, Shandong, China. 5Department of Radiation Oncology, Jining First People’s Hospital, Jiankang Road, Jining 272029, Shandong, China. 6Xun Wang, Xiufen Sun, Zhanguo Sun and Shuang Ge contributed equally to this work. 􀀍 [email: yingxiangszg@163.com](email: yingxiangszg@163.com); [geshuang616@163.com](geshuang616@163.com)  \nR Radiomics model  \nD Dosiomics model  \nRDC Radiomics-dosiomics-clinical model RS Radiomics signature  \nDS Dosiomics signature  \nNLR Neutrophil-to-lymphocyte ratio LMR Lymphocyte-to-monocyte ratio ORR Objective response rate  \nPFS Progression-free survival AUC Area under the curve  \nROC Receiver operating characteristic ROI Region of interest  \nNon-small cell lung cancer (NSCLC) accounts for approximately 75%–80% of all primary lung cancer cases and remains a leading cause of cancer-related death worldwide,","cbCaifUcfvAoMmua","https://ap.wps.com/l/cbCaifUcfvAoMmua","pdf",2438070,11,"English","# Study aim\n# Patient cohorts and model development\n# Prediction targets (ORR and PFS)\n# Evaluation metrics and statistical methods\n# Results and model comparison\n# Clinical implications","[{\"question\":\"What is the main goal of this study?\",\"answer\":\"To develop and validate a machine learning model that combines radiomics, dosiomics, and clinical factors to predict radiotherapy response in locally advanced, unresectable NSCLC.\"},{\"question\":\"How were the patients grouped for training and validation?\",\"answer\":\"A total of 222 patients were divided into training (n = 110), internal validation (n = 28), and external validation (n = 84) cohorts.\"},{\"question\":\"Which outcomes were predicted by the models?\",\"answer\":\"The study predicted objective response rate (ORR) and progression-free survival (PFS) using radiomics, dosiomics, and clinical characteristics.\"}]","Development and validation of a radiomics-dosiomics model for predicting radiotherapy response in locally advanced, unresectable non-small cell lung cancer: a multicenter study | PDF",1790155598,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/51c314321ec3aceb4d89e13d27405a08.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f27b3b4233667c9b111b16147b0fda8.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/77b7a691d5608a0d0f7aff119b95a373.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3eea32410bf83cbbf254a95a0a432975.webp",980,1287]